CD22
Showing 1 - 25 of 7,848
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)
Recruiting
- Central Nervous System Lymphoma
- Human CD19-CD22 Targeted T Cells Injection
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Dec 13, 2022
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)
Enrolling by invitation
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Mar 22, 2023
Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)
Not yet recruiting
- Lymphoma, B-Cell
- CD19 and CD22 targeted CAR-T cells
-
Langfang, Hebei, ChinaHebei Yanda Ludaopei Hospital
Dec 6, 2022
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Azacitidine Injection
- +2 more
- (no location specified)
Oct 15, 2023
Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)
Recruiting
- Hairy Cell Leukemia
- Hairy Cell Leukemia Variant
- CD22CART cell infusion
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)
Not yet recruiting
- Acute Lymphoid Leukemia
- +4 more
- fludarabine
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Trial in Stanford (Fludarabine, Cyclophosphamide, Autologous
Suspended
- B Cell Lymphoma
- +2 more
- Fludarabine
- +2 more
-
Stanford, CaliforniaStanford Medical Center
Sep 8, 2022
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Trial in Tianjin (CD19-CD22 CAR-T cells)
Active, not recruiting
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- CD19-CD22 CAR-T cells
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 2, 2022
Leukemia, Lymphoma Trial in United States (SCRI-CAR22v2)
Recruiting
- Leukemia
- Lymphoma
- SCRI-CAR22v2
-
Los Angeles, California
- +4 more
Jan 18, 2023
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Beijing
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- Autologous humanized anti-CD22 chimeric antigen receptor T cells
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Aug 12, 2022
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B Lineage Lymphoblastic Lymphoma
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
- Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 25, 2023
Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector
Not yet recruiting
- Lymphoid Leukemia
- Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
- Treg CD34+ HSPC (Orca-T)
-
Palo Alto, CaliforniaStanford Cancer Center
Aug 17, 2022
Leukemia Trial in Seattle (Patient-derived CD22-specific CAR T-cells also expressing an EGFRt)
Active, not recruiting
- Leukemia
- Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
-
Seattle, WashingtonSeattle Children's Hospital
Feb 15, 2022
Leukemia, Lymphoma Trial in Canada, United States (Patient-derived CD19- and CD22 specific CAR)
Recruiting
- Leukemia
- Lymphoma
- Patient-derived CD19- and CD22 specific CAR
-
Los Angeles, California
- +4 more
Apr 2, 2022
CD19+ and CD 22+ B-ALL Trial in Langfang (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide,Fludarabine)
Recruiting
- CD19+ and CD 22+ B-ALL
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
- Cyclophosphamide,Fludarabine
-
Langfang, Hebei, ChinaHebei Yanda Ludaopei Hospital
Jan 25, 2022
Non-Hodgkin Lymphoma Trial in Aurora (CD19x22 CAR T Cells)
Active, not recruiting
- Non-Hodgkin Lymphoma
- CD19x22 CAR T Cells
-
Aurora, ColoradoUniversity of Colorado Hospital
Sep 1, 2022
Acute Lymphoblastic Leukemia Trial in Shanghai (Human CD19-CD22 Targeted T Cells Injection)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- Human CD19-CD22 Targeted T Cells Injection
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Jan 24, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Suzhou (CD22/CD19 CAR T and auto-HSCT "sandwich" strategy)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- CD22/CD19 CAR T and auto-HSCT "sandwich" strategy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jul 20, 2022
Refractory and Relapsed B Cell Acute Leukemia Trial in Sanhe (CD19/CD22-Dual-STAR-T)
Suspended
- Refractory and Relapsed B Cell Acute Leukemia
- CD19/CD22-Dual-STAR-T
-
Sanhe, Hebei, ChinaHebei Yanda Ludaopei Hospital
Jan 29, 2022
Acute Lymphocytic Leukemia Trial in Beijing, Tianjin (LCAR-AIO Cells)
Recruiting
- Acute Lymphocytic Leukemia
- LCAR-AIO Cells
-
Beijing, Beijing, China
- +1 more
May 31, 2022
Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase
Recruiting
- Lymphoblastic Leukemia
- +4 more
- Phase I
- Phase II
-
Singapore, SingaporeKK Women's and Children's hospital
Jun 20, 2022
B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL Trial in Stanford (Fludarabine, Cyclophosphamide, CD22 CAR)
Recruiting
- B-ALL
- +3 more
- Fludarabine
- +2 more
-
Stanford, CaliforniaStanford Medical Center
Jan 14, 2022
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022
Not yet recruiting
- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Fludarabine (30 mg/m^2)
- +2 more
- (no location specified)
Jul 25, 2023